Avoiding HIV False Positives (JCM ed.)
Listen now
We can probably all agree that any false positive test result is bad, but I think it’s safe to say that some false positives, like a false positive HIV test for example, is much more anxiety provoking than others. And when it comes to HIV, there have been a number of key advances in the field over the past decade, include the development of improved diagnostics and optimized algorithmic approaches, all of which have allowed for earlier detection of infected patients, and particularly those with acute HIV. Among these advancements has been the development of 4th and 5th generation serologic assays, which offer multiple benefits over prior assay versions, but unfortunately, are not immune to the possibility of false positive results. So, confirmatory test remain a necessary – the challenge though is that depending on the institution and environment, the turnaround time for such confirmatory testing can be prolonged, leaving patients and clinicians in a kind of diagnostic limbo. So, is there a way to minimize the risk of false positive first-tier HIV serologic results? And that is the question will be the focus of our discussion today. Watch this episode: https://youtu.be/kq61A3Jz67U Guests:  Dr. Shivanjali Shankaran - Assistant Professor and ID Clinician in the Division of Infectious Diseases at Rush Medical Center in Chicago Dr. Beverly Sha - Professor of Medicine, also in the Division of Infectious Diseases at Rush Medical Center This episode of Editors in Conversation is brought to you by the Journal of Clinical Microbiology and hosted by JCM Editor in Chief, Alex McAdam and Dr. Elli Theel.  Visit https://journals.asm.org/journal/jcm to read articles and/or submit a manuscript. Follow EIC, Alex McAdam on twitter for JCM updates via https://twitter.com/JClinMicro and co-host, Elli Theel at https://twitter.com/ellitheelphd. Subscribe to the podcast at https://asm.org/eic
More Episodes
As the number of immunocompromised patients rise in our hospitals, the presentation of severe infections caused by HSV and CMV are rising. Most importantly, lack of response and documented resistance are becoming more frequently observed. Topics discussed: The clinical problems caused by...
Published 05/01/23
Published 05/01/23
Susceptibility testing for piperacillin-tazobactam has undergone rapid evolution, largely driven by some surprising results from the MERINO trial, which compared the efficacy of piperacillin-tazobactam and meropenem for treatment of patients with ceftriaxone-resistant E. coli or Klebsiella...
Published 04/08/23